Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The HECT domain and RLD 2 pseudogene (ENSG00000254398; LOC100419574) is classified as a pseudogene, meaning it is a nonfunctional segment of DNA that resembles a functional gene but typically lacks the ability to encode a functional protein product[2]. Pseudogenes are generally considered genomic relics; however, in some cases, they may serve regulatory roles—such as generating noncoding RNAs that can influence the expression of related genes—but there is no specific evidence that this pseudogene has such a function[1][2]. This entry is not a canonical therapeutic target like a receptor, enzyme, transporter, or transcription factor. There is nothing indicating that it plays a direct role in drug action, disease, or as a clinical biomarker. Its presence in genomic databases is for reference and does not mark it as functionally relevant to current pharmacological or clinical practice.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HECT domain and RLD 2 pseudogene.